Auto saved by Logseq

master
Borja Robert 12 months ago
parent bb87cb9b64
commit 6dda1bf11c

@ -50,8 +50,8 @@ date:: [[2023/12]]
- 3 dose regimen - 3 dose regimen
- Continue to include potential to inform future MDA design and improved effectiveness/cost effectiveness of MDAs, improved clinical management - Continue to include potential to inform future MDA design and improved effectiveness/cost effectiveness of MDAs, improved clinical management
- Alejandro to share potential protocol/design for salivary testing of [[Albendazol]] (e.g. 48 hours after dose 3) to complement reported coverage data. - Alejandro to share potential protocol/design for salivary testing of [[Albendazol]] (e.g. 48 hours after dose 3) to complement reported coverage data.
- Economics Contributes also to WP3 (KEMRI) - Economics Contributes also to [[STOP2030/WP3]] ([[KEMRI]])
- GHS RDD to consider options for inclusion of key costing data points - [[GHS/RDD]] to consider options for inclusion of key costing data points
- Discuss with GHS economist - Discuss with GHS economist
- Discuss with KEMRI (e.g. [[Stella Kepha]]) - Discuss with KEMRI (e.g. [[Stella Kepha]])
- Can be informed by ongoing work at [[London School of Hygiene & Tropical Medicine]] for the ALIVE trial (draft anticipated in [[2024/01]]) - Can be informed by ongoing work at [[London School of Hygiene & Tropical Medicine]] for the ALIVE trial (draft anticipated in [[2024/01]])
Loading…
Cancel
Save